AI Variant Interpretation Landscape 2026 — PatSnap Eureka
AI-Powered Variant Interpretation: The 2026 Innovation Landscape
From neoantigen immunogenicity prediction to LLM-guided clinical genomics, this landscape maps the patent and literature signals shaping how AI systems classify and prioritize genomic variants in diagnostics, oncology, and personalized medicine.
Four Technical Clusters Define the AI Variant Interpretation Landscape
AI-powered variant interpretation covers a spectrum of technical approaches applied to the challenge of determining what a genomic or molecular variant means — clinically, functionally, and immunologically. As noted by Scripps Research Institute (2019): "The interpretation of variation in the human genome constitutes one of the most pressing challenges in biomedicine."
Within this dataset, four primary technical domains emerge. The first is genomic variant annotation and clinical classification platforms that integrate multi-database evidence from sources such as ClinVar and gnomAD and apply machine learning models to determine pathogenicity or phenotypic impact. The second domain encompasses neoantigen and immunogenicity prediction systems that use AI models to predict whether mutant peptide sequences will be immunogenic — directly relevant to cancer vaccine development.
The third cluster covers interactive clinical variant interrogation tools that combine real-time genomic data visualization with variant prioritization for diagnostician use. The fourth addresses continuous evidence optimization platforms for variant interpretation that incorporate model auditing, evidence class weighting, and validation workflows. Together, these clusters span the full pipeline from raw variant calling to clinical decision support, reflecting the breadth of innovation now tracked by PatSnap's IP analytics platform.
From 2013 to 2026: How AI Variant Interpretation Evolved
The dataset spans over a decade of innovation, from foundational gene-network querying to multi-modal pMHC-TCR immunogenicity modeling and LLM-based bioinformatics reasoning.
- 2013 GeneMANIA Prediction Server (University of Toronto) — Established the paradigm of functionally extending gene lists using genomics and proteomics data networks. The earliest directly relevant variant interpretation innovation in this dataset.
- 2018 VIPER (University of Münster) — Web-based expert review interface for NGS variant calls integrating the Integrative Genomics Viewer. Demonstrated on datasets exceeding 10,000 calls, indicating progression from database querying toward interactive expert-in-the-loop systems.
- 2019 ai-OMNI / Scripps Research Institute — Introduced NLP-powered summarization of variant knowledge sources, combining search engine access to variant annotation sources with automated summaries.
- 2020–2021 Invitae Corporation (IL) continuous evidence optimization platform and University of Utah's gene.iobio both appeared, signaling a shift toward automated, clinically actionable pipelines with real-time interactive visualization.
- 2022–2023 Accelerating activity in neoantigen/immunogenicity prediction systems grounded in deep learning (Synteka Bio, Neogen TC Co.) and LLM integration into bioinformatics tasks via the Bioinfo-Bench evaluation framework (2023).
- 2024–2026 Emerging generation of AI systems combining pMHC binding prediction, TCR characterization, and immune variant consequence modeling. Zeromics Inc.'s 2026 filing introduces differential immunogenicity indexing — the most forward-looking filing in this dataset.
Patent & Literature Filing Activity: Key Data Visualizations
Data derived from patent and literature records retrieved via PatSnap Eureka. All values reflect signals within this dataset only.
AI Variant Interpretation Filing Activity by Year (2013–2026)
Filings accelerate sharply from 2022 onward, driven primarily by Korean neoantigen prediction patents. 2024 shows the highest single-year count in this dataset.
Korean Assignee Filing Share — Neoantigen AI Prediction (2022–2026)
Neogen TC Co. leads with 3 filings, followed by Zeromics Inc. with 2. No single assignee holds more than 2 filings in the core variant interpretation space.
Key Technology Approaches in AI Variant Interpretation
Four distinct innovation clusters have emerged from this patent and literature dataset, each addressing a different layer of the variant interpretation pipeline.
Multi-Database Variant Annotation with NLP & Search Intelligence
This approach aggregates variant knowledge from distributed databases (ClinVar, gnomAD, OMIM, etc.) and applies NLP to synthesize and surface clinically relevant evidence. Scripps Research Institute's ai-OMNI (2019) introduced NLP-powered summarization of variant knowledge sources. The BIOVARS/Pynoma toolkit (2022) enables programmatic batch queries across gnomAD and population-specific databases. NCBI's ClinVar and related resources underpin this cluster's data infrastructure.
NLP · gnomAD · ClinVar · search enginesContinuous Evidence Optimization & Auditable Interpretation Platforms
Invitae Corporation's molecular evidence platform patent (IL, 2020) is the most directly relevant patent claim in this landscape to production-grade clinical variant interpretation infrastructure. The core claim is a computer-implemented method for recording evidence, monitoring model performance across evidence classes, and automatically selecting the best-performing model using disjoint validation data. IP strategists entering the clinical variant interpretation platform space should assess the scope of this claim across jurisdictions.
Invitae · model auditing · evidence optimizationInteractive Clinical Variant Interrogation & Visualization
The gene.iobio platform (University of Utah, 2021) presents a real-time, web-based application for clinical variant prioritization that replaces tabular variant reports with interactive genomic visualizations, explicitly targeting the diagnostician workflow. VIPER (University of Münster, 2018) integrates the Integrative Genomics Viewer into a web application enabling analysts to iterate through NGS variant calls, apply filters, and record decisions — demonstrated on datasets exceeding 10,000 calls. The gap between these academic tools and commercial patent filings remains wide.
gene.iobio · VIPER · real-time · diagnostician UXAI-Powered Neoantigen & Immunogenicity Variant Prediction
This cluster focuses specifically on predicting the immune consequences of somatic variants — whether a mutant peptide will bind MHC, be presented, and elicit a T-cell response. This is among the most active sub-domains in the dataset by recent filing count. Zeromics Inc.'s AI model ingests calculated characteristics of both mutant and primitive epitopes plus a computed differential index. Neogen TC Co. trains AI models to classify pMHC binding using iterative label refinement. Synteka Bio uses molecular dynamics simulation combined with AI to rank neoantigen candidates by MHC binding affinity and TCR activity.
pMHC · TCR · neoantigen · immunogenicity · KR filingsKey Assignees in AI Variant Interpretation (2013–2026)
South Korea dominates by patent filing count. US academic institutions lead foundational literature. No single assignee accounts for more than 2 filings in the core variant interpretation space — indicating an early-to-mid stage competitive landscape.
Four Forward-Looking Signals from 2023–2026
Among the most recent filings and publications in this dataset, four directional signals stand out as indicators of where AI variant interpretation is heading.
Differential Immunogenicity Indexing for Somatic Variants (2024–2026)
Zeromics Inc.'s 2026-filed patent introduces the concept of a computed differential index between mutant and wild-type (primitive) epitope immunogenicity values as input to a pre-trained AI model — moving beyond single-sequence MHC affinity prediction toward comparative variant consequence modeling. This is the most forward-looking filing in this dataset.
Multi-Modal pMHC-TCR Immunogenicity Prediction (2024)
Neogen TC Co.'s 2024 filing expands beyond pMHC binding to model the full pMHC-TCR interaction complex, generating immunogenicity predictions that capture whether a T-cell receptor will actually recognize a presented variant-derived peptide — a significant expansion of the prediction scope.
What This Landscape Means for IP Strategists and R&D Teams
The neoantigen immunogenicity prediction sub-domain is the most active patent-filing zone in this dataset, with at least 5 distinct Korean assignees filing between 2022 and 2026. R&D teams building cancer vaccine platforms should monitor Korean IP closely and consider freedom-to-operate analysis against the pMHC-TCR modeling claims now emerging from Neogen TC Co. and Zeromics Inc. PatSnap's life sciences solutions are designed precisely for this type of competitive IP monitoring.
Invitae Corporation's continuous evidence optimization patent (IL, 2020) represents a potentially broad foundational claim over auditable, model-selection-based variant interpretation pipelines. IP strategists entering the clinical variant interpretation platform space should assess the scope of this claim across jurisdictions.
The gap between academic tooling (gene.iobio, VIPER, ai-OMNI) and commercial patent filings remains wide, suggesting that many workflow innovations are currently in open-source or publication form rather than protected IP — creating both opportunity for commercialization and risk of rapid competitive entry. According to WIPO, AI-related patent filings in life sciences have grown substantially over the past decade, making proactive IP monitoring essential.
Korean biotech companies are emerging as the primary commercial filers in immunogenicity and neoantigen variant prediction, while US and European academic institutions continue to lead foundational methods. Strategic partnerships or licensing from Korean innovators may be essential for global players seeking comprehensive IP coverage in the personalized cancer vaccine space. PatSnap customers in oncology use these exact workflows to identify licensing opportunities before competitors do.
AI-Powered Variant Interpretation — Key Questions Answered
AI-powered variant interpretation encompasses computational systems that apply machine learning, deep learning, natural language processing, and large language models to classify, prioritize, and predict the clinical or functional significance of genomic and molecular variants. This field sits at the intersection of precision medicine and artificial intelligence, where the ability to rapidly and accurately interpret the consequences of genetic variation is becoming foundational to diagnostics, oncology, and personalized therapeutics.
South Korea (KR) is the dominant jurisdiction by patent filing count, with approximately 10 distinct KR-jurisdiction patent filings identified across the variant interpretation and neoantigen prediction sub-domains. Key Korean assignees include Zeromics Inc., Neogen TC Co., Synteka Bio Inc., Gradient Bioconvergence Inc., and BioNTech US Inc. (KR-filed).
The neoantigen immunogenicity prediction sub-domain is the most active patent-filing zone in this dataset, with at least 5 distinct Korean assignees filing between 2022 and 2026. R&D teams building cancer vaccine platforms should monitor Korean IP closely and consider freedom-to-operate analysis against the pMHC-TCR modeling claims now emerging from Neogen TC Co. and Zeromics Inc.
The Bioinfo-Bench framework (2023) documents systematic evaluation of large language models on bioinformatics knowledge tasks including variant-related question answering, reflecting a trend toward deploying foundation models as analytical assistants rather than just search tools. LLM integration into variant interpretation is nascent but accelerating, and the next generation of variant interpretation products will likely incorporate foundation model reasoning layers.
Invitae Corporation's continuous evidence optimization patent (IL, 2020) represents a potentially broad foundational claim over auditable, model-selection-based variant interpretation pipelines. The core claim is a computer-implemented method for recording evidence, monitoring model performance across evidence classes, and automatically selecting the best-performing model using disjoint validation data — representing the most direct patent claim in this landscape to production-grade clinical variant interpretation infrastructure.
Among retrieved records, the earliest directly relevant variant interpretation innovation dates to 2013, with the GeneMANIA Prediction Server (University of Toronto, 2013). Between 2019 and 2021, a cluster of more sophisticated AI-integrated platforms emerged. From 2022 onward, the dataset reflects accelerating activity in neoantigen/immunogenicity prediction systems grounded in deep learning and LLM integration into bioinformatics tasks. The most recent signals (2024–2026) show an emerging generation of AI systems that combine pMHC binding prediction, TCR characterization, and immune variant consequence modeling.
Still have questions about variant interpretation IP? Let PatSnap Eureka answer them for you.
Ask PatSnap Eureka Your QuestionAccelerate Your Variant Interpretation IP Strategy
Join 18,000+ innovators already using PatSnap Eureka to map neoantigen prediction IP, identify freedom-to-operate risks, and find white-space opportunities in AI-powered genomics.
References
- Retrieval of whole human genome clinical variant information through search motors
- Gene.iobio: an interactive web tool for versatile, clinically-driven variant interrogation and prioritization
- Molecular evidence platform for auditable, continuous optimization of variant interpretation in genetic and genomic testing and analysis
- VIPER: a web application for rapid expert review of variant calls
- Pynoma, PyABraOM and BIOVARS: Towards genetic variant data acquisition and integration
- Translation of Genomics into Precision Medicine with Artificial Intelligence: A Narrative Review
- Method for predicting immunogenicity of neoantigen epitope and device using the same
- Method for predicting immunogenicity of neoantigen epitope and device using the same
- Apparatus and method for generating immunopeptidome pMHC information using artificial intelligence
- Apparatus and method for generating immunopeptidome pMHC information using artificial intelligence
- Apparatus and method for generating immunogenicity information using artificial intelligence technology
- Prediction system and method of artificial intelligence model based neoantigen immunotherapeutics using molecular dynamic bigdata
- Neoantigen prediction device, neoantigen prediction method and computer program
- Method and systems for prediction of HLA class II-specific epitopes and characterization of CD4+ T cells
- Bioinfo-Bench: A Simple Benchmark Framework for LLM Bioinformatics Skills Evaluation
- Artificial intelligence system and method for assessing autoimmune disease prognosis
- GeneMANIA Prediction Server 2013 Update
- eVITTA: a web-based visualization and inference toolbox for transcriptome analysis
- WIPO — World Intellectual Property Organization
- NCBI — National Center for Biotechnology Information (ClinVar, gnomAD)
- Scripps Research Institute
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. This landscape is derived from a limited set of patent and literature records retrieved across targeted searches and represents a snapshot of innovation signals within this dataset only.
PatSnap Eureka searches patents and research to answer instantly.